• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Conserved epitopes

Ganseerpel

Advisory Board, Senior Moderator
Several human peptide epitopes that have been described and characterized show evidence of remarkably little mutation over many generations of viral evolution. In the most recent outbreaks of H5N1 virus, some of these peptides are conserved in viruses isolated from human patients

<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=bottom colSpan=4>Table. Conservation of human NP and M1 epitopes between H1N1 PR8 and 3 human isolates of H5N1 viruses (A/Hong Kong/156/1997, A/Hong Kong/213/2003, and A/Vietnam/1203/2004)*

</TD></TR><TR><TD colSpan=4><HR noShade SIZE=1></TD></TR><TR><TD vAlign=bottom>Epitope
</TD><TD vAlign=bottom>HLA restriction
</TD><TD vAlign=bottom>PR8 sequence
</TD><TD vAlign=bottom>Conservation

</TD></TR><TR><TD colSpan=4><HR noShade SIZE=1></TD></TR><TR><TD vAlign=top>NP 383–391
</TD><TD vAlign=top>B*2705
</TD><TD vAlign=top>SRYWAIRTR
</TD><TD vAlign=top>3/3 identical

</TD></TR><TR><TD vAlign=top>NP 418–426
</TD><TD vAlign=top>B*3501
</TD><TD vAlign=top>LPFDRTTIM
</TD><TD vAlign=top>0/3 identical

</TD></TR><TR><TD vAlign=top>NP 44–52
</TD><TD vAlign=top>A*01
</TD><TD vAlign=top>CTELKLSDY
</TD><TD vAlign=top>2/3 identical (156 Y9Q)

</TD></TR><TR><TD vAlign=top>NP 265–273
</TD><TD vAlign=top>A*03
</TD><TD vAlign=top>ILRGSVAHK
</TD><TD vAlign=top>3/3 identical

</TD></TR><TR><TD vAlign=top>NP 188–198
</TD><TD vAlign=top>A*1101
</TD><TD vAlign=top>TMVMELVRMIK
</TD><TD vAlign=top>3/3 V7I mutation

</TD></TR><TR><TD vAlign=top>NP 380–388
</TD><TD vAlign=top>B*08
</TD><TD vAlign=top>ELRSRYWAI
</TD><TD vAlign=top>3/3 identical

</TD></TR><TR><TD vAlign=top>NP 174–184
</TD><TD vAlign=top>B*2705
</TD><TD vAlign=top>RRSGAAGAAVK
</TD><TD vAlign=top>2/3 identical (156 V10I)

</TD></TR><TR><TD vAlign=top>M1 58–66
</TD><TD vAlign=top>A*0201
</TD><TD vAlign=top>GILGFVFTL
</TD><TD vAlign=top>3/3 identical

</TD></TR><TR><TD vAlign=top>M1 27–35
</TD><TD vAlign=top>A*03
</TD><TD vAlign=top>RLEDVFAGK
</TD><TD vAlign=top>2/3 mutated (1203, 213 both R1K)

</TD></TR><TR><TD vAlign=top>M1 13–21
</TD><TD vAlign=top>A*1101
</TD><TD vAlign=top>SIIPSGPLK
</TD><TD vAlign=top>3/3 identical

</TD></TR></TBODY></TABLE>

Reference:
Cell-mediated Protection in Influenza Infection Paul G. Thomas,* Rachael Keating CDC Vol. 12, No. 1 January 2006
 
Back
Top